Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Unknown 1Suspended 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 3Burkitt Lymphoma 3Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Plasmablastic Lymphoma 2Lymphoma, B-Cell 2Oropharyngeal Neoplasms 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Primary Effusion 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1HIV Infections 1Enteropathy-Associated T-Cell Lymphoma 1Cranial Nerve Diseases 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1

Interventions

Cyclophosphamide 25Rituximab 22fludarabine 14Lenalidomide 10Vincristine 8Doxorubicin 8Prednisone 7Etoposide 7fludarabine phosphate 6Immunotherapy, Adoptive 5polatuzumab vedotin 4Cytarabine 4CT-P10 4Bendamustine Hydrochloride 4Antigens, CD19 4tocilizumab 3Gemcitabine 3Dexamethasone 3Carboplatin 3venetoclax 2veltuzumab 2prednylidene 2ofatumumab 2obinutuzumab 2ixazomib 2ibrutinib 2etoposide phosphate 2deltacortene 2carmustine, poliferprosan 20 drug combination 2acalabrutinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, B-Cell × prednylidene × Clear all
NCT03704714 2022-08-15

Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

Northwestern University

Phase 1/2 Suspended
30 enrolled
Lymphoid

Lymphoma, B-Cell

NCT02481310 2022-02-21

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

Northwestern University

Phase 1/2 Unknown
38 enrolled 12 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡